{"created":"2023-05-18T10:11:27.156580+00:00","id":3196,"links":{},"metadata":{"_buckets":{"deposit":"254556dd-d857-4e48-8358-86b54ed837ba"},"_deposit":{"created_by":1,"id":"3196","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"3196"},"status":"published"},"_oai":{"id":"oai:yamanashi.repo.nii.ac.jp:00003196","sets":["205:251:303"]},"author_link":["15015","15014","15012","15013","15016"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1990","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"34","bibliographicPageStart":"25","bibliographicVolumeNumber":"5","bibliographic_titles":[{"bibliographic_title":"山梨医科大学雑誌"},{"bibliographic_title":"山梨医科大学雑誌","bibliographic_titleLang":"en"}]}]},"item_10001_creator_2":{"attribute_name":"著者名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"YAMAMOTO, Yasuyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"IIZUKA, Hidehiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAMOTO, Masayuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TASAKA, Kachio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SUGAHARA, Katsuhiko"}],"nameIdentifiers":[{}]}]},"item_10001_description_5":{"attribute_name":"内容","attribute_value_mlt":[{"subitem_description":"We performed immunochemotherapy using a continuous infusion of recombinant interleukin 2 (IL2) and intermittent one-shot-injections of Adriamycin (ADR) administered directly to the hepatic artery in 6 cases of advanced hepatocellular carcinoma (HCC). Although the observation periods were short, the tumors reduced in size; most notably, a massive tumor in the right lobe disappeared in one case. After reviewing the 6 patients with HCC, we demonstrated a possible cause of ADR as a kind of immuno-modifier. In an in vitro study, the susceptibility of subpopulations of lymphocytes to ADR was variable with the suppressor T cell being more susceptible to ADR compared to the helper T cell. In HCC patients, the ratio of the suppressor T cells to the helper T cells (suppressor/helper ratio) was significantly higher than that of the healthy controls. Thus, following the administration of the optimal dose of ADR, specific decrease in the suppressor T cell and increase in the helper T cell in response to ADR can be obtained for the recovery of the suppressor/helper ratio. Moreover, ADR-treated lymphocytes of HCC patients exhibited constant killer activity in the presence of IL2. Although the optimal dose of ADR for clinical use may be within a very narrow range, ADR combined with IL2 following tumor mass-reduction treatments may restore the immunity of advanced HCC patients and prolong their survival.","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.34429/00003189","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山梨医科大学医学会"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10044054","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0912-0025","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-27"}],"displaytype":"detail","filename":"AN10044054_05_01_03.pdf","filesize":[{"value":"1.6 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"AN10044054_05_01_03.pdf","url":"https://yamanashi.repo.nii.ac.jp/record/3196/files/AN10044054_05_01_03.pdf"},"version_id":"4ac2db7e-b417-41b9-a2ec-1eac34b8fc34"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Immunochemotherapy"},{"subitem_subject":"Recombinant interleukin 2"},{"subitem_subject":"Adriamycin"},{"subitem_subject":"Liver cancer"},{"subitem_subject":"Surface marker"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<Original Article> A Proposal of Effctive Immunochemotherapy Using Recombinant Interleukin 2 and Adriamycin, and Its Theoretical Background","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<Original Article> A Proposal of Effctive Immunochemotherapy Using Recombinant Interleukin 2 and Adriamycin, and Its Theoretical Background"}]},"item_type_id":"10001","owner":"1","path":["303"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-05-18"},"publish_date":"2010-05-18","publish_status":"0","recid":"3196","relation_version_is_last":true,"title":["<Original Article> A Proposal of Effctive Immunochemotherapy Using Recombinant Interleukin 2 and Adriamycin, and Its Theoretical Background"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-10-11T07:41:41.236490+00:00"}